New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
07:17 EDTHZNPHorizon Pharma price target raised to $25 from $18 at Stifel
Stifel increased its price target on Horizon as the firm thinks that the company's acquisition of Vidara has left it in "ideal position" to become profitable and meet its revenue and EBITDA guidance. The firm thinks the company's drug portfolio is poised to perform well, and keeps a Buy rating on the shares.
News For HZNP From The Last 14 Days
Check below for free stories on HZNP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 19, 2014
16:57 EDTHZNPHorizon Pharma files automatic ordinary share shelf
10:46 EDTHZNPHorizon Pharma backs FY15 revenue view $380M-$405M, consensus $376.94M
Backs FYT15 adjusted EBITDA view $150M-$170M
10:45 EDTHZNPHorizon Pharma backs FY14 revenue view $270M-$280M, consensus $277.56M
Subscribe for More Information
September 18, 2014
19:50 EDTHZNPHorizon Pharma trading halted, pending news
Subscribe for More Information
09:19 EDTHZNPHorizon Pharma announces holder approval of Vidara acquisition
Subscribe for More Information
September 16, 2014
06:21 EDTHZNPHorizon Pharma to host special shareholder meeting
Special shareholder meeting to consider and seek shareholder approval of the acquisition of Vidara Therapeutics, will be held in Deerfield, IL on September 18 at 9 am.
September 15, 2014
08:12 EDTHZNPHorizon Pharma valuation at attractive entry point, says Cowen
Subscribe for More Information
September 9, 2014
10:09 EDTHZNPHorizon Pharma initiated with an Outperform at Avondale (pre-open)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use